Terms: = Germ cell tumor AND NBN, AT-V2, 4683, ENSG00000104320, ATV, FLJ10155, NBS, AT-V1, MGC87362, NBS1 AND Clinical Outcome
10 results:
1. Restoration of the molecular clock is tumor suppressive in neuroblastoma.
Moreno-Smith M; Milazzo G; Tao L; Fekry B; Zhu B; Mohammad MA; Di Giacomo S; Borkar R; Reddy KRK; Capasso M; Vasudevan SA; Sumazin P; Hicks J; Putluri N; Perini G; Eckel-Mahan K; Burris TP; Barbieri E
Nat Commun; 2021 Jun; 12(1):4006. PubMed ID: 34183658
[TBL] [Abstract] [Full Text] [Related]
2. Implication of Image-Defined Risk Factors for the Extent of Surgical Resection and clinical outcome in Patients with Pelvic Neuroblastoma.
Froeba-Pohl A; von Schweinitz D; Muehling J; Paolini M; Hubertus J
Eur J Pediatr Surg; 2021 Aug; 31(4):362-366. PubMed ID: 32862422
[TBL] [Abstract] [Full Text] [Related]
3. Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma.
Pottoo FH; Barkat MA; Harshita ; Ansari MA; Javed MN; Sajid Jamal QM; Kamal MA
Semin Cancer Biol; 2021 Feb; 69():100-108. PubMed ID: 31562954
[TBL] [Abstract] [Full Text] [Related]
4. MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma.
Ferrucci F; Ciaccio R; Monticelli S; Pigini P; di Giacomo S; Purgato S; Erriquez D; Bernardoni R; Norris M; Haber M; Milazzo G; Perini G
Biochim Biophys Acta Gene Regul Mech; 2018 Mar; 1861(3):235-245. PubMed ID: 29408445
[TBL] [Abstract] [Full Text] [Related]
5. Identification of aberrant methylation regions in neuroblastoma by screening of tissue-specific differentially methylated regions.
Sugito K; Kawashima H; Uekusa S; Yoshizawa S; Hoshi R; Furuya T; Kaneda H; Hosoda T; Masuko T; Ohashi K; Ikeda T; Koshinaga T; Fujiwara K; Igarashi J; Ghosh S; Held WA; Nagase H
Pediatr Blood Cancer; 2013 Mar; 60(3):383-9. PubMed ID: 22911660
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive analysis of tumoral DNA content reveals clonal ploidy heterogeneity as a marker with prognostic significance in locoregional neuroblastoma.
Mora J; Lavarino C; Alaminos M; Cheung NK; Ríos J; de Torres C; Illei P; Juan G; Gerald WL
Genes Chromosomes Cancer; 2007 Apr; 46(4):385-96. PubMed ID: 17243159
[TBL] [Abstract] [Full Text] [Related]
7. PPM1D is a potential target for 17q gain in neuroblastoma.
Saito-Ohara F; Imoto I; Inoue J; Hosoi H; Nakagawara A; Sugimoto T; Inazawa J
Cancer Res; 2003 Apr; 63(8):1876-83. PubMed ID: 12702577
[TBL] [Abstract] [Full Text] [Related]
8. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract] [Full Text] [Related]
9. Risk of unfavorable character among neuroblastomas detected through mass screening. The Japanese Infantile Neuroblastoma Cooperative Study.
Tanaka T; Matsumura T; Iehara T; Sawada T
Med Pediatr Oncol; 2000 Dec; 35(6):705-7. PubMed ID: 11107151
[TBL] [Abstract] [Full Text] [Related]
10. The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors.
Maitra A; Yashima K; Rathi A; Timmons CF; Rogers BB; Shay JW; Gazdar AF
Cancer; 1999 Feb; 85(3):741-9. PubMed ID: 10091748
[TBL] [Abstract] [Full Text] [Related]
